Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients

NCT01687582 · Completed

Last updated 2026-05-28

This clinical trial tests whether GLP-1 analogs, a type of diabetes medication, can improve psoriasis symptoms in adults with both type 2 diabetes and psoriasis.

Status Completed The study has finished.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 10 people

Who can join Ages 20–75 · all sexes

Timeline Started 2012-01 · est. completion 2013-03

Where 1 site · Belgium

What this study is testing ClinicalTrials.gov NCT01687582 ↗

Description as written by the study sponsor.

The aim of the study is to evaluate after 4 to 6 months the effects of a GLP-1 analog treatment on psoriatic skin lesions in patients with type 2 diabetes.

Treatments tested

GLP-1 analog also known as Liraglutide, Victoza or Exenatide, Byetta. Drug

GLP-1 analog treatment

Main thing measured	Improvement of PASI score
Sponsor	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Conditions studied	Type 2 Diabetes, Psoriasis
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01687582 ↗